Get the Stockscreener App
9.625
2.50%
0.235
After Hours:
9.65
0.025
+0.26%
Daxor Corporation stock is traded at $9.625, with a volume of 10,110.
It is up +2.50% in the last 24 hours and up +24.35% over the past month.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
See More
Previous Close:
$9.39
Open:
$9.23
24h Volume:
10,110
Relative Volume:
1.83
Market Cap:
$43.42M
Revenue:
$2.61M
Net Income/Loss:
$1.69M
P/E Ratio:
32.05
EPS:
0.3003
Net Cash Flow:
-
1W Performance:
+6.94%
1M Performance:
+24.35%
6M Performance:
+21.07%
1Y Performance:
+0.36%
1-Day Range:
$8.76
$9.7319
1-Week Range:
$8.68
$9.75
52-Week Range:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
Name
Daxor Corporation
Sector
Industry
Phone
212-330-8500
Address
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Compare DXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
9.625 | 43.42M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
534.19 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.97 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.11 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
256.21 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
219.00 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-19 | Initiated | Ascendiant Capital Markets | Buy |
Daxor Corporation Stock (DXR) Latest News
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals - The Globe and Mail
(DXR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
(DXR) Proactive Strategies - news.stocktradersdaily.com
(DXR) Investment Analysis - news.stocktradersdaily.com
Daxor announces new findings from Duke University on BVA - TipRanks
Daxor (DXR) Highlights Key Heart Failure Study Results | DXR Sto - GuruFocus
Daxor Announces Duke University Study on Blood Volume - GlobeNewswire
Duke Research Reveals 40% of Heart Failure Patients Misdiagnosed with Anemia, Study Shows - Stock Titan
Daxor (DXR) Expands Diagnostic Solutions Across U.S. Healthcare Systems | DXR Stock News - GuruFocus
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems - GlobeNewswire
Daxor announces opening of new BVA program at Florida center - TipRanks
Daxor (DXR) Launches Advanced BVA Program in Tampa Bay Healthcare Center | DXR Stock News - GuruFocus
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology - GlobeNewswire
Renaissance Technologies LLC Has $214,000 Stock Holdings in Daxor Co. (NASDAQ:DXR) - Defense World
Daxor announces expansion of BVA capabilities in three new hospitals - TipRanks
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Part - GuruFocus
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Partnerships | DXR Stock News - GuruFocus
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance - GlobeNewswire
NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) Head-To-Head Comparison - Defense World
Daxor Corporation Secures Funding for Blood Volume Analyzer Study - Medical Product Outsourcing
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN
Critical Analysis: Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) - The AM Reporter
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions - The Manila Times
Daxor Corporation to Exhibit at the 45th International - GlobeNewswire
Revolutionary Blood Volume Analysis: How Daxor's 98% Accurate Tech is Transforming Heart and Lung Care - Stock Titan
Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) Head to Head Review - Defense World
(DXR) Trading Report - news.stocktradersdaily.com
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic - GlobeNewswire
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation Stock (DXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Daxor Corporation Stock (DXR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Michel Robert J | Chief Financial Officer |
Mar 10 '25 |
Buy |
8.00 |
1,000 |
8,000 |
17,050 |
| Feldschuh Michael Richard | Chief Executive Officer |
Mar 10 '25 |
Buy |
7.68 |
3,360 |
25,805 |
210,852 |
0.43%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):